Cryo-Cell International enters the back half of May with a compliance clock running. NYSE American accepted the cord blood bank's plan to regain listing compliance on May 8, giving the company until September 9 to meet its continued listing standards.
The delisting backstory is the sharpest tension here. The 8-K filed this week confirmed the exchange's acceptance — a reprieve, not a resolution. The stock slipped 3.5% on May 8 to $3.45, and is down just over 1% on the week. At a market cap of roughly $28 million, the float is thin and the margin for error is narrow. How the company navigates that September deadline will define the next few months.
Short interest tells a story of rapid retreat rather than pressure. Estimated short interest has more than halved over the past month — falling around 49% — to just 0.075% of the free float. That is an immaterially small position by any measure. The pullback from late April is stark: shorts briefly climbed toward 12,000–13,000 shares in the April 24 vicinity before collapsing back. Borrow conditions reflect how little conviction remains. Cost to borrow runs at 0.77% — essentially a GC rate, far off the 1.28% peak seen in early March. Availability is effectively unconstrained, with the ORTEX availability reading at 9,999% of short interest, meaning there is no lending market tension whatsoever. The ORTEX short score of 26.1 is low and drifting gently lower all week, reinforcing that the short thesis has largely dissolved.
The ownership picture is the most structurally interesting element. CEO and Chairman David Portnoy controls 19.1% of shares. His brother Mark holds a further 11.6%. Together the two Portnoys sit on more than 30% of the company. Camac Partners disclosed a fresh 430,900-share position in its March 25 filing — building a 5.3% stake from zero. That institutional entry, alongside the dense insider concentration, means a thin free float is even thinner in practice. The latest insider buy data dates from November 2025 and shows David Portnoy steadily accumulating at around $4.05–$4.13 per share across a cluster of small trades; the stock now trades below those levels at $3.45.
The most recent earnings print, filed April 14, beat on both lines — Q1 EPS of $0.01 against a $(0.10) estimate, with revenue of $7.68 million edging past the $7.63 million consensus. The stock moved 3.1% the next day. Over the subsequent five days it drifted back 1.1%. On April 28, Cryo-Cell added a positive operational note: it received FACT re-accreditation for cord blood collection and banking through April 2029, the longest independently validated quality track record among US private cord blood banks. The next earnings event is pencilled in for July 10.
Analyst coverage is thin and stale — a single Hold rating from Maxim Group, downgraded from Buy in October 2025, more than 200 days ago. No recent price target is on record. That data should not be treated as current guidance on valuation.
The one-stock factor scores worth noting: the short score ranks in the 94th percentile relative to the broader universe, meaning CCEL's short positioning is lighter than nearly all peers — that's consistent with a near-zero SI reading. The DTC rank of 82 similarly flags that days-to-cover is tight, not because shorts are entrenched but because the float is so small that even a handful of shares represents a meaningful fraction of daily volume.
What to watch: whether the company files its compliance remediation plan milestones on schedule ahead of the September 9 deadline — that regulatory clock, not short positioning or borrow dynamics, is the live variable now.
See the live data behind this article on ORTEX.
Open CCEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
